How to integrate more effective systemic treatment into combined modality treatment?

Slides:

Advertisements

Similar presentations

Oncology management of CNS tumours Neil Burnet University of Cambridge Department of Oncology & Oncology Centre, Addenbrookes Hospital ECRIC CNS study.

Advertisements

Barbara Vanderstraeten Ghent University Hospital 19 January 2008

Herceptin as a Phase 0 Imaging Example. Phase 0 Trials in Oncology Drug Development Steven M. Larson, M.D. Nuclear Medicine Svc, Department of Radiology.

Texture Analysis for Radiotherapy So-Yeon Park 31 st of Dec, 2013.

Multi-tracer analysis for patient’s following using multi-observation statistical image fusion : a feasibility study S. David 1, M. Hatt 1, P. Fernandez.

Yujun Guo Kent State University August PRESENTATION A Binarization Approach for CT-MR Registration Using Normalized Mutual Information.

Stereotactic Body Radiation Therapy (SBRT): The optimal indication for operable tumors in inoperable patients D.Katsochi 1, S.Kosmidis 1, A.Fotopoulou.

Trevor Thang Department of Medical Biophysics, Western University QUALITY ASSURANCE OF MRI FOR ADAPTIVE RADIOTHERAPY: PRELIMINARY INVESTIGATIONS Six Week.

PET/CT & PET/MRI Radiopharmacy

ISSSMA June 3 rd Advanced quantification in oncology PET Irène Buvat IMNC – UMR 8165 CNRS – Paris 11 University Orsay, France

Derek Martinig Suzanne Lane Julia Barnscher.  FDG (18-fluoro-2-deoxyglucose) – Radioactive F in place of O in glucose  Fluoride decays back to Oxygen.

Tumor Localization Techniques Richard Kao April 10, 2001 Computer Integrated Surgery II.

Update on 18 F-Fluorodeoxyglucose/Positron Emission Tomography and Positron Emission Tomography/ Computed Tomography Imaging of Squamous Head and Neck.

ACRIN 6671/GOG 0233 Consent for Research Study A study for Women with Advanced Cervical Cancer: Learning whether a PET/CT scan using an imaging agent called.

Sequential vs. concurrent chemoradiotherapy for locally advanced non-small cell carcinoma.

Quantitative Brain Structure Analysis on MR Images

Vincent Grégoire, Peter Levendag et. al. DELINEATION OF THE CTV IN THE N 0 NECK OF PATIENTS WITH HEAD & NECK SQUAMOUS CELL CARCINOMA. ANATOMICAL BOUNDARIES.

Functional Imaging with PET for Sarcoma Rodney Hicks, MD, FRACP Director, Centre for Molecular Imaging Guy Toner, MD, FRACP Director, Medical Oncology.

1 4D: Adaptive Radiotherapy & Tomotherapy Bhudatt Paliwal, PhD Professor Departments of Human Oncology & Medical Physics University of Wisconsin Madison.

RTOG1106: Randomized Phase IIR Trial of Personalized Adaptive Radiotherapy Based on Mid-treatment FDG-PET in Locally Advanced NSCLC P.I.: Feng-Ming (Spring)

PET in Colorectal Cancer. Indications for FDG PET Rising marker, (-) CT/MRI Nonspecific findings on CT/MRI, recurrence or post treatment changes? Known.

BREAST MRI IN RADIATION THERAPY PLANNING MARSHA HALEY, M.D. ASSISTANT PROFESSOR UNIVERSITY OF PITTSBURGH CANCER INSTITUTE PITTSBURGH, PENNSYLVANIA, USA.

May 19-20, Quantitation, both single point and longitudinal*, of tumor metabolism via FDG-PET/CT that can be used practically and efficiently as.

Jeffrey Yap, PhD Ron Kikinis, MD Wendy Plesniak, PhD -1- CTSA at RSNA 2009 PET/CT Analysis using 3D Slicer Jeffrey Yap PhD Ron Kikinis MD Wendy Plesniak.

NEW IMAGING MODALITIES IN BREAST CANCER MANAGEMENT Dr Rachel Boutemy.

IMRT. 3DCRT vs IMRT Treated Volume Tumor Target Volume Intensity Modulation Treated Volume Critical structure Target Volume Collimator "Classical" Conformation.

WELCOME. PET/CT CASE REVIEW COURSE JANUARY 31 ST PASADENA CONVENTION CENTER LOS ANGELES RADIOLOGIC SOCIETY MID WINTER MEETING.

IHE Workshop – June 2006What IHE Delivers 1 Todd Kantchev, Siemens Molecular Imaging Jerold Wallis, Mallinckrodt Institute of Radiology Kevin O’Donnell,

Early prediction of response Functional imaging Microarrays Proteomics.

CARATTERIZZAZIONE DI LESIONI DI ORIGINE SCONOSCIUTA SOSPETTE PER LESIONI MALIGNE NEI PAZIENTI PEDIATRICI: POSSIBILE RUOLO DEL 18F-FDG PET/CT A.Cistaro.

Albert J. Chang, MD, PhD 1 Farrokh Dehdashti, MD 2 Perry W. Grigsby, MD, MS 1 Department of Radiation Oncology 1 Department of Radiology and Nuclear Medicine.

Can PET/CT and PET FDG predict Chemotherapy response in lung cancer patients? By: Megan Broscious.

SARC018: A SARC PILOT MULTICENTER STUDY OF PREOPERATIVE RADIATION AND SURGERY IN PATIENTS WITH HIGH- RISK DESMOID TUMORS Robert S. Benjamin, M.D.

Monday Case of the Day A) The treatment was successful: The bremsstrahlung SPECT (Fig 2) indicates that 90 Y was deposited in the tumor. B) The treatment.

Preoperative staging of hilar cholangiocarcinoma by dual-modality PET/CT. DR SIKANDAR YASHODA HOSPITALS HYDERABAD.

The use of Radiotherapy in Cancer.. What is radiotherapy? The treatment of cancer with ionising radiation is called Radiotherapy or Radiation Oncology.

핵의학과 PK 18 조 68 번 주리히 Case presentation 2 Disease review 3 Journal review.

Background: Malignant pleural mesothelioma (MPM) is a rare and aggressive tumor with a complex growth pattern. Imaging plays a crucial role in diagnosis.

Addition of Chemotherapy to Preoperative Radiotherapy Improves Outcomes in Rectal Cancer Slideset on: Bosset JF, Calais G, Mineur L, et al. Enhanced tumorocidal.

©2005 Surgical Planning Laboratory, ARR Slide 1 AMIGO: Advanced Multimodality Image-Guided Operating room Randy Ellis, Ph.D.

IHE-RO 2008 Managed Workflow Profiles Bruce Curran Assistant Professor / Univ of Michigan.

Molecular Imaging “101” The Role of Molecular Imaging in Cancer Briefing and Roundtable Washington, DC July 22, 2008 Martin G. Pomper, MD, PhD Russell.

CT and PET imaging in non-small cell lung cancer

A primary esophageal MALT lymphoma patient with Helicobacter pylori infection achieved complete remission after H. pylori eradication without anti-lymphoma.

Automated delineation of brain structures in patients undergoing radiotherapy for primary brain tumors: From atlas to dose–volume histograms Manuel Conson,

Comparison of carina- versus bony anatomy-based registration for setup verification in esophageal cancer image-guided radiotherapy Melanie Machiels* 1,

Computational Neuroanatomy for Dummies

Dosimetric Consequences of 3D Versus 4D PET/CT for Target Delineation of Lung Stereotactic Radiotherapy Shankar Siva, MBBS, FRANZCR, Brent Chesson, BAppSc.

Clinical and Translational Radiation Oncology

A, baseline and 4-week PET scan from patient 2 (MET c

Evolving options in the management of esophageal perforation

Yuko Ogawa, Koichiro Abe, Akiko Sakoda, Hiromi Onizuka, Shuji Sakai

Physics and Imaging in Radiation Oncology

Objective Multiply two binomials..

18F-FDG PET-CT and MRI co-registered knee assessment after ACL transection in an in vivo canine model M. Menendez, D. Clark, K. Binzel, B. Hettlich,

FDG-PET and FDG-PET/CT for Diagnosing Infection in Patients with Multiple Vascular Bypass Grafts: A Report of Two Cases V.E. de Meijer, A.W.H. van de.

Changes in apparent diffusion coefficient radiomics features during dose-painted radiotherapy and high dose rate brachytherapy for prostate cancer Sangjune.

Monitoring anatomical changes of individual patients using statistical process control during head-and-neck radiotherapy Nicholas J. Lowther, David A.

Representative CT and PET/CT images of three patients with NSCLCs

Combined morphologic and metabolic pipeline for Positron emission tomography/computed tomography based radiotherapy response evaluation in locally advanced.

The role of positron emission tomography for non-small cell lung cancer Albert J. Chang, MD, PhD, Farrokh Dehdashti, MD, Jeffrey D. Bradley, MD Practical.

A Patient With BRAF V600E Lung Adenocarcinoma Responding to Vemurafenib Oliver Gautschi, MD, Chantal Pauli, MD, Klaus Strobel, MD, Astrid Hirschmann,

Ustekinumab treatment is associated with decreased systemic and vascular inflammation in patients with moderate-to-severe psoriasis: Feasibility study.

Correlation between FMISO-PET based hypoxia in the primary tumour and in lymph node metastases in locally advanced HNSCC patients Anna Bandurska-Luque,

Successful AZD9291 Therapy Based on Circulating T790M

The rationale for MR-only treatment planning for external radiotherapy

Fig. 1. Examples of the response evaluation using MR-CAD, DWI and PET/CT. (A) DCE-MRI analysis using MR-CAD provided information regarding the size, volume.

Representative CT and PET/CT images of three patients with NSCLCs

Fig. 1.Representative images of 18F-FDG PET-CT and immunohistochemical staining for TILs. (A) Whole-body 18F-FDG PET image demonstrates increased FDG uptake.

Figure 12a Pitfalls in N staging at CT and PET

Presentation transcript:

How to integrate more effective systemic treatment into combined modality treatment?

T0 Pre-treatment Treatment T1T2TN … Anatomical Functional Time Information Combination of physics and biology for treatment optimization/adaptation

10 patients PETFDG F-MISO CT MR TME (10) 5 patients PET FDG FLT CT MR TME (7) …….. Week 1 Week 2 Week 3Week 4Week 5 Surgery 1 2 3

123 MR Delineation MR: manually

1 2 3 CT FDG CT FLT

Signal to Background Daisne JF, Radioth Oncol, 2003 J. Lee, 2006 background tumor Watershed & Clustering FDG FMISO FLT Delineation FDG signal: SBR & WCA

Deformed FDG FMISO signal Delineation FLT/FMISO signal: WCA + ROI (FDG)

MeanSTDEVMeanSTDEVMeanSTDEV Before RT 27,1 (100%)  16,5 18,3 (100%)  12,4 15,5 (100%)  10,6 During RT 13,4 (47%)  10,2 11,4 (65%)  8,1 7,2 (46%)  6,7 After RT 6,7 (25%)  5,7 4,9 (25%)  4,3 2,5 (13%)  2,3 n=15 MR FDG (SBR)FDG (WCA)

FMISO (WCA) n=10 FDG (WCA)FLT (WCA) n=5 MeanSTDEVMeanSTDEV Before RT14,8  7,3 5,2  3,8 During RT7,3  7,6 1,6  1,5 MeanSTDEVMeanSTDEV Before RT14,5  6,0 9,2  3,3 During RT5,3  3,9 4,0  2,4

Multi-temporal image registration of FDG PET-CT images Rigid within tumor volume Biological Follow-up imaging during RT treatment before radiotherapy during therapy after therapy CT Image Registration CT PET

FDG volumeMismatch FDGMR volumeMR mismatch MeanBefore RT1647%2769% During RT753%1379% After RT268%785% rangeBefore RT4-4620%-100% %-100% During RT2-2712%-99%4-4260%-99% After RT0-735%-100%0,5-2044%-100% mismatch A-B = B-A/B (%) mismatch B-A = A-B/A (%) mismatch A-B = 0% Mismatch FDG-MR